- Poster presentation
- Open Access
Contrast-enhanced whole heart coronary MRI with a bolus infusion of gadobenate dimeglumine at 1.5 t
© Hu et al; licensee BioMed Central Ltd. 2010
Published: 21 January 2010
The potential benefits of contrast agents have been studied for coronary MRI; however the contrast timing/injection rate and sequence remain to be optimized. We investigated three infusion schemes (bolus, hybrid, slow) of gadobenate dimeglumine ([Gd-BOPTA]2-, MultiHance; Bracco Imaging SpA, Milan, Italy), a high relaxivity extracellular contrast agent, for improved whole-heart coronary MRI by measuring blood T1 kinetics. Subsequently, we developed a contrast-enhanced whole-heart coronary MRI method at 1.5 T using an inversion-recovery SSFP sequence acquired after a bolus infusion.
Four healthy adult subjects were imaged three times each using three infusion schemes: a) bolus (0.2mmol/kg@2ml/s), b) hybrid (0.1mmol/kg@2ml/s plus email@example.com/s), and c) slow (0.2mmol/kg@ 0.3ml/s). A Look-Locker sequence was used for quantitative T1 measurements. Subsequently, seven healthy subjects were recruited for evaluation of a contrast-enhanced whole-heart coronary MRI with a bolus infusion. Free-breathing SSFP coronary MRI (TR/TE/α = 3.6/1.8/90°, FOV = 300 × 300 × 120 mm3, resolution = 1.3 × 1.3 × 1.3 mm3, T2-Prep, ×2 accelerated) was performed before contrast injection. Gd-BOPTA (0.2mmol/kg@2ml/s) was injected intravenously, immediately followed by a Look-Locker sequence to visually determine the optimal inversion time. A contrast-enhanced whole-heart coronary was then acquired with identical imaging parameters with the exception of replacing the T2-Prep with a non-selective inversion pulse. For both acquisitions, a noise scan was performed immediately after acquisition. The blood SNR and blood-myocardium CNR were measured.
Contrast-enhanced whole heart coronary MRI with a bolus infusion of Gd-BOPTA using inversion-recovery SSFP at 1.5 T results in enhanced SNR and CNR.
This article is published under license to BioMed Central Ltd.